Summit Trail Advisors LLC Sells 502 Shares of Zoetis Inc. (NYSE:ZTS)

Summit Trail Advisors LLC reduced its position in Zoetis Inc. (NYSE:ZTS) by 8.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 5,273 shares of the company’s stock after selling 502 shares during the period. Summit Trail Advisors LLC’s holdings in Zoetis were worth $1,041,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Blue Bell Private Wealth Management LLC lifted its position in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares during the period. Independence Bank of Kentucky lifted its holdings in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after buying an additional 130 shares during the period. Ramirez Asset Management Inc. bought a new stake in Zoetis during the 3rd quarter valued at $35,000. First Financial Corp IN boosted its position in Zoetis by 57.2% during the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after acquiring an additional 79 shares in the last quarter. Finally, Bogart Wealth LLC increased its holdings in shares of Zoetis by 188.9% in the 3rd quarter. Bogart Wealth LLC now owns 260 shares of the company’s stock valued at $45,000 after acquiring an additional 170 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZTS has been the subject of a number of analyst reports. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Stifel Nicolaus decreased their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Barclays cut their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Finally, The Goldman Sachs Group decreased their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $212.38.

Zoetis Stock Performance

Shares of NYSE:ZTS traded down $1.12 on Monday, hitting $165.95. 3,080,329 shares of the company were exchanged, compared to its average volume of 3,177,335. The firm has a market capitalization of $75.72 billion, a P/E ratio of 32.12, a price-to-earnings-growth ratio of 2.62 and a beta of 0.86. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The stock’s 50 day moving average price is $168.88 and its 200 day moving average price is $178.93.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The company had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.31 EPS. Sell-side analysts predict that Zoetis Inc. will post 5.77 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.04%. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the sale, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 2,209 shares of company stock valued at $371,293. 0.16% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.